HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target.

March 12, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acelyrin maintains a Buy rating and a $30 price target from HC Wainwright & Co., indicating a positive outlook.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Acelyrin's potential. This endorsement is likely to instill investor confidence and could lead to a positive short-term impact on SLRN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100